

11-03-06

IFW

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|----|------------------------|------------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | | Application Number | 10/507,928-Conf. #6804 |
| | | Filing Date | March 19, 2003 |
| | | First Named Inventor | Ralph P. Braun |
| | | Art Unit | 1633 |
| | | Examiner Name | Not Yet Assigned |
| Total Number of Pages in This Submission | 07 | Attorney Docket Number | HO-P03173US0-10505259 |

| ENCLOSURES (Check all that apply) | | |
|---|--|--|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Certificate of Mailing (1 page) 22 out of 24 cited references 1 Return Postcard |
| <div>Remarks</div> | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
|--|-----------------------------|----------|--------|
| Firm Name | FULBRIGHT & JAWORSKI L.L.P. | | |
| Signature | | | |
| Printed name | Melissa W. Acosta | | |
| Date | November 2, 2006 | Reg. No. | 45,872 |



Docket No.: HO-P03173US0-10505259
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ralph P. Braun et al.

Application No.: 10/507,928

Confirmation No.: 6804

Filed: March 19, 2003

Art Unit: 1633

For: IMIDAZOQUINOLINEAMINES A
ADJUVANTS IN HIV DNA VACCINATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an


admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P03173US0.

Dated: November 2, 2006

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.


2200 Ross Avenue, Suite 2800

Dallas, Texas 75201-2784

(214) 855-7163

(214) 855-8200 (Fax)

Attorney for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/507,928 #6804 |
| | | | | Filing Date | March 19, 2003 |
| | | | | First Named Inventor | Ralph P. Braun |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 2 | Attorney Docket Number | HO-P03173US0-10505259 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | AA | US-5,958,895 | Sep. 28, 1999 | Pachuk et al. | |
| | AB | US-2003/0139364-A1 | Jul. 24, 2003 | Kreig et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | BA | WO 1998/50567 | Nov. 12, -1998 | Abbott Laboratories | | |
| | BB | WO 2001/46228 | Jun. 28, 2001 | Glaxo Group Limited | | |
| | BC | WO 2005/025614 | Mar. 24, 2005 | Glaxo Group Limited | | |


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CA | "Interferon-gamma as adjuvant in immunocompromised mice," Immunology, Abstract of Heath AW, August 1989, 67(4): 520-4. | |
| | CB | "Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation," Clin Exp Immunol, Abstract of Holland GP, November 1990, 82(2): 221-226. | |
| | CC | "Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice", Clin Exp Immunol, Abstract of Playfair JH, January 1987, 67(1):5-10. | |
| | CD | "Specific immune responses of dairy cattle after primary inoculation with recombinant bovine interferon-gamma as an adjuvant when vaccinating against mastitis", Am J Vet Res. Abstract of Pighetti GM, June 1996, 57(6):819-24. | |
| | CE | XIANG Z., et al., "Manipulation of the immune response to a plasmid-encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines", Immunity, Vol. 2, February 1995, pp. 129-135. | |
| | CF | BAEK, KM et al. "Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65", Vaccine, 21, May 2003, pp. 3684-3689. | |
| | CG | HAYASHI, F. et al., "Toll-like receptors stimulate human neutrophil function," Blood, 1 October 2003, Vol. 102, No. 7, pp. 2660-2669. | |
| | CH | HARRISON, C.J., "Effect of S28463 as an adjuvant for an immunotherapeutic HSV glycoprotein D (gD) DNA vaccine: Reduction of recurrent genital HSV disease in guinea pigs," Abstracts of the 36th ICAAC, page 185. | |
| | CI | HEMMI, H., et al. "Small anti-viral compounds active immune cells via the TLR7 MyD88-dependent signaling pathway," Natuer Immunology, Vol. 3, No. 2, February 2002, pp. 196-200. | |
| | CJ | JURK, M. et al., "Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848," Nature Immunology, Vol. 3, No. 6, June 2002, page 499. | |
| | CK | KURT- JONES, E., et al., "Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

25713962.1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-----------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/507,928 #6804 |
| | | | | Filing Date | March 19, 2003 |
| | | | | First Named Inventor | Ralph P. Braun |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | Not Yet Assigned |
| | | | | Attorney Docket Number | HO-P03173US0-10505259 |
| Sheet | 2 | of | 2 | | |


| | | | |
|--|----|---|--|
| | | enhances TLR2-mediated interleukin 8 responses in neutrophils," Blood, 1 September 2002, Vol. 100, No. 5, pp. 1860-1868. | |
| | CL | LEHNER, T., et al., "The role of $\gamma\delta$ T cells in generating antiviral factors and β -chemokines in protection against mucosal simian immunodeficiency virus infection," Eur. Immunol May 2000, pp. 2245-2256. | |
| | CM | MILLER, R.L., et al., "Imiquimod applied topically: a novel immune response modifier and new class of drug," International journal of Immuno pharmacology 21, July 1998, pp. 1-14. | |
| | CN | SAUDER, D., "Immunomodulatory and pharmacologic properties of imiquimod," American Academy of Dermatology, Inc., 2000. pp. S6-S11. | |
| | CO | SCHEERLINCK, J-P., "Genetic adjuvants for DNA vaccines," Vaccine 19, 2001, pp. 2647-2656. | |
| | CP | STANLEY, M.A., "Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential," Clinical & Experimental Dermatology, Vol. 27, No. 7, October 2992, pp. 571-577(7). | |
| | CQ | THOMSEN, L.L., "Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccinations by particle-mediated immunotherapeutic delivery," Vaccine 22, 2004, pp. 1799-1809. | |
| | CR | ZUBBER, A.K., "Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA," Vaccine 22, 2004, pp. 1791-1798. | |
| | CS | BRETT, S., "Strategies to Adjuvanties Particle Mediated Delivery of DNA Immunotherapeutic," Presentation given at meeting in Oxford, March 2006, pp. 1-6. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

25713962.1



Application No.: 10/507,928

Attorney Docket No.: HO-P03173US0-1010505259

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 482723499 US in an envelope addressed to:

Mail Stop Amendmnt
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on November 2, 2006
Date


Signature

John Pallivathukal

Typed or printed name of person signing Certificate

N/A

Registration Number, if applicable

(214) 855-8375

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)
Information Disclosure Statement (2 pages)
PTO Form SB-08 (2 pages)
22 out of 24 cited references
1 Return Postcard